Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis
DMD imposes a substantial cost and healthcare resource burden on patients and the healthcare system. The results suggest a high unmet need that requires the development of novel therapies to treat DMD.
Authors
- Mena T. Scavina (ORCID: https://orcid.org/0000-0002-1371-9765)
- Patricia Dorling
- Anna Stachel
- A.K. Talaga
- Nate Posner
- Jose Alvir
Institutions
- Pfizer (United States) (US)
- Nemours Children's Health System (US)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1007/s41669-025-00612-z
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Pfizer Pharmaceuticals